Cargando…
The efficacy of topical 0.1% mometasone furoate for treating symptomatic severe phimosis: A comparison of two treatment regimens
BACKGROUND: Twice daily 0.1% mometasone furoate is an effective treatment for phimosis in children. However, mometasone furoate has an important therapeutic advantage because it is effective in once-daily applications. This study was to compare the efficacy of two different topical 0.1% mometasone f...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664212/ https://www.ncbi.nlm.nih.gov/pubmed/36389352 http://dx.doi.org/10.3389/fped.2022.1025899 |
_version_ | 1784831052527697920 |
---|---|
author | Zhou, Guanglun Yin, Jianchun Sun, Junjie Zhu, Wenbin Jin, Shiyang Li, Shou-lin |
author_facet | Zhou, Guanglun Yin, Jianchun Sun, Junjie Zhu, Wenbin Jin, Shiyang Li, Shou-lin |
author_sort | Zhou, Guanglun |
collection | PubMed |
description | BACKGROUND: Twice daily 0.1% mometasone furoate is an effective treatment for phimosis in children. However, mometasone furoate has an important therapeutic advantage because it is effective in once-daily applications. This study was to compare the efficacy of two different topical 0.1% mometasone furoate regimens for the treatment of symptomatic severe phimosis in pediatric patients. METHODS: A total of 1,689 patients with symptomatic severe phimosis classified by the Kikiros system were prospectively enrolled in the study from March 2018 to February 2021. A total of 855 patients received 0.1% mometasone furoate twice-daily (BID group) and 834 patients received 0.1% mometasone furoate once-daily (QD group) for 4 weeks. RESULTS: A total of 1,595 boys completed the treatment (798 and 797 in the BID and QD groups, respectively). The success rate of the BID group was higher than that of the QD group at the end of week 2 (44.8% vs. 33.3%, P < 0.05), while there was no difference in the success rate at 4 weeks and 3 months between the two groups (70.7% vs. 69.7%, and 66.8% vs. 64.9%, respectively) (P > 0.05). In both treatment groups, the success rate of grade 5 phimosis was lower than that of grade 4 at 2 weeks, 4 weeks, and 3 months. A total of 83 patients experienced recurrence of phimosis. Only fifteen patients had local mild adverse drug reactions. CONCLUSION: Topical application of 0.1% mometasone furoate once-daily or twice-daily for 4 weeks had comparable efficacy in children with symptomatic severe phimosis. A once a day regimen may be more suitable for children. Topical steroid application is more effective in children with low-grade phimosis than those with high-grade phimosis. |
format | Online Article Text |
id | pubmed-9664212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96642122022-11-15 The efficacy of topical 0.1% mometasone furoate for treating symptomatic severe phimosis: A comparison of two treatment regimens Zhou, Guanglun Yin, Jianchun Sun, Junjie Zhu, Wenbin Jin, Shiyang Li, Shou-lin Front Pediatr Pediatrics BACKGROUND: Twice daily 0.1% mometasone furoate is an effective treatment for phimosis in children. However, mometasone furoate has an important therapeutic advantage because it is effective in once-daily applications. This study was to compare the efficacy of two different topical 0.1% mometasone furoate regimens for the treatment of symptomatic severe phimosis in pediatric patients. METHODS: A total of 1,689 patients with symptomatic severe phimosis classified by the Kikiros system were prospectively enrolled in the study from March 2018 to February 2021. A total of 855 patients received 0.1% mometasone furoate twice-daily (BID group) and 834 patients received 0.1% mometasone furoate once-daily (QD group) for 4 weeks. RESULTS: A total of 1,595 boys completed the treatment (798 and 797 in the BID and QD groups, respectively). The success rate of the BID group was higher than that of the QD group at the end of week 2 (44.8% vs. 33.3%, P < 0.05), while there was no difference in the success rate at 4 weeks and 3 months between the two groups (70.7% vs. 69.7%, and 66.8% vs. 64.9%, respectively) (P > 0.05). In both treatment groups, the success rate of grade 5 phimosis was lower than that of grade 4 at 2 weeks, 4 weeks, and 3 months. A total of 83 patients experienced recurrence of phimosis. Only fifteen patients had local mild adverse drug reactions. CONCLUSION: Topical application of 0.1% mometasone furoate once-daily or twice-daily for 4 weeks had comparable efficacy in children with symptomatic severe phimosis. A once a day regimen may be more suitable for children. Topical steroid application is more effective in children with low-grade phimosis than those with high-grade phimosis. Frontiers Media S.A. 2022-11-01 /pmc/articles/PMC9664212/ /pubmed/36389352 http://dx.doi.org/10.3389/fped.2022.1025899 Text en © 2022 Zhou, Yin, Sun, Zhu, Jin and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Zhou, Guanglun Yin, Jianchun Sun, Junjie Zhu, Wenbin Jin, Shiyang Li, Shou-lin The efficacy of topical 0.1% mometasone furoate for treating symptomatic severe phimosis: A comparison of two treatment regimens |
title | The efficacy of topical 0.1% mometasone furoate for treating symptomatic severe phimosis: A comparison of two treatment regimens |
title_full | The efficacy of topical 0.1% mometasone furoate for treating symptomatic severe phimosis: A comparison of two treatment regimens |
title_fullStr | The efficacy of topical 0.1% mometasone furoate for treating symptomatic severe phimosis: A comparison of two treatment regimens |
title_full_unstemmed | The efficacy of topical 0.1% mometasone furoate for treating symptomatic severe phimosis: A comparison of two treatment regimens |
title_short | The efficacy of topical 0.1% mometasone furoate for treating symptomatic severe phimosis: A comparison of two treatment regimens |
title_sort | efficacy of topical 0.1% mometasone furoate for treating symptomatic severe phimosis: a comparison of two treatment regimens |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664212/ https://www.ncbi.nlm.nih.gov/pubmed/36389352 http://dx.doi.org/10.3389/fped.2022.1025899 |
work_keys_str_mv | AT zhouguanglun theefficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT yinjianchun theefficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT sunjunjie theefficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT zhuwenbin theefficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT jinshiyang theefficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT lishoulin theefficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT zhouguanglun efficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT yinjianchun efficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT sunjunjie efficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT zhuwenbin efficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT jinshiyang efficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens AT lishoulin efficacyoftopical01mometasonefuroatefortreatingsymptomaticseverephimosisacomparisonoftwotreatmentregimens |